종양학 기반 In-vivo CRO 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 적응증별(혈액암, 고형암), 모델별(동종 모델, 환자 유래 이종 이식, 이종 이식), 지역별 및 경쟁별(2020-2030년)
Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region & Competition, 2020-2030F
상품코드:1771202
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
종양학 기반 In-vivo CRO 세계 시장 규모는 2024년에 12억 4,000만 달러로 평가되었습니다. 2030년까지 연평균 복합 성장률(CAGR) 8.29%를 보일 것으로 예측됩니다.
이 역동적인 분야는 라이브 모델에서 전문적인 전임상 및 임상 연구 서비스를 제공함으로써 암 치료법을 발전시키는 데 중요한 역할을 하고 있습니다. 전 세계 암 발병률 증가와 표적치료에 대한 수요가 성장을 견인하고 있습니다. 바이오 CRO는 첨단 시험 플랫폼과 전문가의 통찰력을 통해 제약회사와 바이오테크 기업이 의약품 개발을 가속화하고, 비용 효율성을 개선하며, 규제 요건을 충족할 수 있도록 돕습니다. 고해상도 이미징, 인간화 모델, AI 기반 예측 도구와 같은 기술 혁신은 생체 내 연구 능력에 혁명을 불러일으키고 있습니다. 개인 맞춤형 의료의 급격한 증가로 CRO가 환자별 유전자 프로파일에 맞추어 연구를 수행하는 등 이 분야는 더욱 변화하고 있으며, CRO, 학술 기관, 의료 서비스 제공업체 간의 협력은 혁신을 촉진하고 연구 파이프라인을 확장하고 있습니다. 암 분야가 의약품 개발의 중심이 되는 가운데, in-vivo CRO는 암 치료를 재구성하는 데 있어 점점 더 중요한 역할을 하게 될 것입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
12억 4,000만 달러
시장 규모 : 2030년
19억 8,000만 달러
2025-2030년 CAGR
8.29%
급성장 부문
고형암
최대 시장
북미
시장 성장 촉진요인
암 유병률 증가
주요 시장 이슈
암 조사의 복잡성
주요 시장 동향
개인 맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
적응증별(혈액암, 고형 암)
모델별(동종 모델, 환자 유래 이종 이식, 이종 이식)
지역별
기업별(2024년)
시장 맵
제6장 북미의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 종양학 기반 In-vivo CRO 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병(M&A)
치료 유형 발매
제13장 세계의 종양학 기반 In-vivo CRO 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체 치료법 위협
제15장 경쟁 구도
Charles River Laboratories, Inc.
ICON PLC
Thermo Fisher Scientific Inc.
Eurofins Scientific SE
Taconic Biosciences, Inc.
Crown Biosciene, Inc.
LabCorp
WuXi AppTec Co., Ltd.
Evotec SE
The Jackson Laboratory
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Oncology Based In-vivo CRO Market was valued at USD 1.24 billion in 2024 and is projected to grow at a CAGR of 8.29% through 2030. This dynamic sector plays a critical role in advancing cancer therapeutics by providing specialized preclinical and clinical research services in live models. Growth is propelled by the increasing global burden of cancer and the demand for targeted treatments. In-vivo CROs help pharmaceutical and biotech companies accelerate drug development, improve cost efficiency, and meet regulatory demands through advanced testing platforms and expert insights. Technological innovations, such as high-resolution imaging, humanized models, and AI-based predictive tools, are revolutionizing in-vivo research capabilities. The surge in personalized medicine is further transforming the field, with CROs tailoring research to match patient-specific genetic profiles. Collaborations among CROs, academic institutions, and healthcare providers are fostering innovation and expanding the research pipeline. As oncology remains central in drug development, in-vivo CROs are set to play an increasingly vital role in reshaping cancer care.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1.24 Billion
Market Size 2030
USD 1.98 Billion
CAGR 2025-2030
8.29%
Fastest Growing Segment
Solid Tumour
Largest Market
North America
Key Market Drivers
Rising Prevalence of Cancer
The growing incidence of cancer is significantly accelerating the expansion of the oncology-based in vivo CRO market. According to WHO 2024 data, there were 20 million new cancer cases and 9.7 million deaths in 2022, with over 53.5 million individuals living within five years of a diagnosis. This widespread impact, particularly in underserved populations, underscores a pressing need for timely and effective treatment development. As cancer's complexity increases, so does the demand for highly specialized research capabilities offered by in vivo CROs. These organizations support pharmaceutical and biotech firms in executing intricate studies that address the multifactorial nature of cancer. With advancements in personalized medicine, there's a growing reliance on CROs to develop models tailored to specific genetic profiles. The outsourcing trend is further intensified by the race to launch new therapies, pushing companies to partner with CROs to boost efficiency. In this rapidly evolving research environment, in vivo CROs provide critical infrastructure, expertise, and innovation, driving their continued growth and importance in cancer therapy development.
Key Market Challenges
Complexity of Cancer Research
The inherent complexity of cancer research presents a significant challenge to the growth of the oncology-based in vivo CRO market. With numerous cancer types, genetic mutations, and constantly shifting treatment paradigms, delivering accurate and relevant in vivo results requires a high level of specialization. Conducting studies that replicate the complex behavior of tumors within living organisms demands advanced methodologies, cutting-edge equipment, and interdisciplinary knowledge-all of which can burden the operational capacities of CROs and their clients. Furthermore, staying aligned with rapidly emerging scientific discoveries increases pressure on these organizations to continuously adapt. Successfully navigating the intricacies of genetic interactions, tumor microenvironments, and treatment responses necessitates not only technological sophistication but also a deep understanding of oncological mechanisms. This complexity limits the availability of skilled professionals, escalates costs, and lengthens research timelines, thereby posing considerable obstacles to scalability and market expansion.
Key Market Trends
Personalized Medicine
The evolution of personalized medicine is significantly influencing the growth of the oncology-based in vivo CRO market. As treatment strategies increasingly account for individual genetic and molecular profiles, the need for tailored preclinical research has grown substantially. In vivo CROs are instrumental in this shift, providing animal models that closely replicate patient-specific genetic markers and tumor behaviors. These models enable precise analysis of treatment efficacy and safety, paving the way for more accurate and effective therapeutic solutions. The complexity of this approach requires advanced tools and scientific expertise, both of which CROs are well-equipped to offer. As pharmaceutical and biotech companies aim to develop more targeted therapies with fewer side effects, they increasingly rely on CROs to conduct studies that serve as a bridge between early-stage research and clinical application. This trend highlights the expanding role of in vivo CROs in advancing precision oncology, cementing their strategic importance in the era of personalized healthcare.
Key Market Players
Charles River Laboratories, Inc.
ICON PLC
Thermo Fisher Scientific Inc.
Eurofins Scientific SE
Taconic Biosciences, Inc.
Crown Biosciene, Inc.
LabCorp
WuXi AppTec Co., Ltd.
Evotec SE
The Jackson Laboratory
Report Scope:
In this report, the global Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oncology Based In-vivo CRO Market, By Indication:
Blood Cancer
Solid Tumor
Oncology Based In-vivo CRO Market, By Model:
Syngeneic Model
Patient Derived Xenograft
Xenograft
Oncology Based In-vivo CRO Market, By Region:
North America
Europe
South America
Asia Pacific
Middle East & Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.
Available Customizations:
Oncology Based In-vivo CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Based In-vivo CRO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Blood Cancer, Solid Tumor)
5.2.2. By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Oncology Based In-vivo CRO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Model
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Based In-vivo CRO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Model
6.3.2. Canada Oncology Based In-vivo CRO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Model
6.3.3. Mexico Oncology Based In-vivo CRO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Model
7. Europe Oncology Based In-vivo CRO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Model
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Based In-vivo CRO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Model
7.3.2. United Kingdom Oncology Based In-vivo CRO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Model
7.3.3. Italy Oncology Based In-vivo CRO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Indication
7.3.3.2.2. By Model
7.3.4. France Oncology Based In-vivo CRO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Model
7.3.5. Spain Oncology Based In-vivo CRO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Model
8. Asia-Pacific Oncology Based In-vivo CRO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Model
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Oncology Based In-vivo CRO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Model
8.3.2. India Oncology Based In-vivo CRO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Model
8.3.3. Japan Oncology Based In-vivo CRO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Model
8.3.4. South Korea Oncology Based In-vivo CRO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By Model
8.3.5. Australia Oncology Based In-vivo CRO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By Model
9. South America Oncology Based In-vivo CRO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Model
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Oncology Based In-vivo CRO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Model
9.3.2. Argentina Oncology Based In-vivo CRO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Model
9.3.3. Colombia Oncology Based In-vivo CRO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Model
10. Middle East and Africa Oncology Based In-vivo CRO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Model
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Oncology Based In-vivo CRO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Model
10.3.2. Saudi Arabia Oncology Based In-vivo CRO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Model
10.3.3. UAE Oncology Based In-vivo CRO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Model
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Treatment Type Launches
13. Global Oncology Based In-vivo CRO Market: SWOT Analysis
